Low dose of serotonin-acting chemical improves blood sugar tolerance

An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press. Importantly, the researchers found, those effects of the drug occurred at a low dose that had no influence on feeding behavior, body weight, activity level, or energy expenditure.

The decades-old drug compound, known as m-chlorophenylpiperazine (mCPP), triggers serotonin receptors in the brain. The findings suggest a new strategy for treating the rising tide of people with type 2 diabetes via targeting the so-called serotonin 2C (5-HT2C) receptors.

“Though just a first step, this work provides a new direction in the search for novel pathways and molecules in the brain to target for the treatment of type 2 diabetes,” said Lora Heisler of the University of Cambridge. “The challenge now is to come up with drugs that selectively target 5-HT2C receptors safely and effectively.”

mCPP has primarily been used in scientific studies of the serotonin pathway and may not itself be appropriate for type 2 diabetes treatment due to its other known effects, Heisler added. Heisler’s collaborators included Joel Elmquist of the University of Texas Southwestern Medical Center and Andrew Butler of Louisiana State University System.

Serotonin is a chemical nerve messenger with effects on physiology and behavior, including mood, sleep, and appetite, that are mediated by multiple serotonin receptors clustered into seven distinct families that are widely expressed in the central and/or peripheral nervous systems, the researchers explained. Earlier studies had explored serotonin-acting drugs in treating obesity, but the possibility of a direct role for serotonin in the development and treatment of type 2 diabetes has received little attention, they said.

Earlier studies revealed that mice lacking the 5-HT2C receptor develop insulin resistance and type 2 diabetes and later overeat and become obese. In the current study, the researchers examined whether a drug that acts on 5-HT2C receptors could improve glucose tolerance. They show in mouse models of obesity and insulin resistance that the drug does improve blood sugar levels. Moreover, it does so even at concentrations that do not lead to reductions in food intake or body weight.

The researchers further report evidence that the serotonin-acting drug may work by stimulating “a-melanocyte-stimulating hormone” (a-MSH) in the brain’s arcuate nucleus, a portion of the hypothalamus important for appetite control. They show that the primary effect of the drug on glucose balance requires activation of one type of a-MSH receptor, called melanocortin-4 receptors (MC4R).

“Our findings add to emerging evidence that the brain may have important influences on glucose metabolism and insulin action,” Heisler added.

While the findings do link serotonin pathways to improved blood sugar tolerance, serotonin supplements would not produce this effect, Heisler noted. That’s because serotonin taken in through the diet cannot cross the blood-brain barrier to reach the critical receptors.

“The identification of new classes of antidiabetic agents is a clinical imperative,” the researchers concluded. “The findings presented here identify a novel therapeutic application for a class of pharmacological compounds developed more than two decades ago. We demonstrate that 5-HT2C receptor agonists significantly improve glucose tolerance and [lower insulin levels in mouse] models of obesity and type 2 diabetes via an MC4R-dependent mechanism. These findings not only delineate specific neuronal pathways of relevance to a highly prevalent metabolic disease but also suggest that 5-HT2C receptor agonists may prove an effective and mechanistically novel treatment for type 2 diabetes.”

Source: Cell Press

Related stories:

Probing Question: Fishhooks of addiction
When the American writer Theodore Roethke taught at Penn State from 1936 to 1943, he was known for three things: being a good poet, coaching the men’s tennis team, and falling down drunk, perhaps the latter more than the former. Roethke, a brilliant and tortured man, knew well the seduction of drink and the agony of addiction. In his poem “Journey Into the Interior,” Roethke writes, “In the long journey out of the self, / There are many detours, washed-out interrupted raw places / Where the shale slides dangerously / And the back wheels hang almost over the edge / At the sudden veering, the moment of turning.”
Spiritual effects of hallucinogens persist, researchers report
In a follow-up to research showing that psilocybin, a substance contained in "sacred mushrooms," produces substantial spiritual effects, a Johns Hopkins team reports that those beneficial effects appear to last more than a year.
Insomnia patients often denied sleep treatment when they have mental health conditions
Patients with insomnia who are diagnosed with accompanying mental health ailments often are not prescribed medication that will help them sleep – which could then make related anxiety or depression worse, new research suggests.
New genetic research into nicotine addiction shows promise for personalized treatment
Whether a smoking-cessation drug will enable you to quit smoking may depend on your genes, according to new genotyping research from the Centre for Addiction and Mental Health (CAMH). The study, published in the September issue of the journal Biological Psychiatry, found that the enzyme known to metabolize both the smoking cessation drug bupropion and nicotine is highly genetically variable in all ethnicities and influences smoking cessation.
Post-marketing studies finding adverse events in drugs used in children
The Food and Drug Administration Modernization Act (FDAMA, 1997), designed to stimulate more drug safety studies in children, has resulted in more than 130 label changes since its inception nearly six years ago, according to researchers at Duke Children's Hospital. Their analysis appears in the September issue of Pediatrics.
Sex differences seen in response to common antidepressant
Women with depression may be much more likely than men to get relief from a commonly used, inexpensive antidepressant drug, a new national study finds. But many members of both sexes may find that it helps ease their depression symptoms.
Likely cause of postpartum blues and depression identified
Unique biochemical crosstalk that enables a fetus to get nutrition and oxygen from its mother's blood just may cause common postpartum blues, researchers say.
Use of sildenafil associated with improvement in antidepressant-related sexual dysfunction in women
Women with sexual dysfunction caused by the use of antidepressants experienced a reduction in adverse sexual effects with use of sildenafil, commonly known as the erectile dysfunction medication Viagra, according to a study in the July 23/30 issue of JAMA.

News discussion:

Medicine & Health news